Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin
and how well it works when given with frontline chemotherapy in treating patients with newly
diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab
ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used
in chemotherapy work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute
lymphoblastic leukemia.
-
Click here for details...
This phase II/III trial studies how well daunorubicin and cytarabine with or without
uproleselan works in treating older adult patients with acute myeloid leukemia receiving
intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin and
cytarabine, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Uproleselan may
prevent cancer from returning or getting worse. Giving daunorubicin and cytarabine with
uproleselan may work better in treating patients with acute myeloid leukemia compared to
daunorubicin and cytarabine alone.
-
Click here for details...
This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual
treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia
who have not received previous treatment. The addition of venetoclax to the usual treatment
might prevent chronic lymphocytic leukemia from returning. This trial also will investigate
whether patients who receive ibrutinib plus obinutuzumab plus venetoclax and have no
detectable chronic lymphocytic leukemia after 1 year of treatment, can stop taking ibrutinib.
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may
interfere with the ability of cancer cells to grow and spread. Venetoclax is in a class of
medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer
cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving ibrutinib and
obinutuzumab with venetoclax may work better at treating chronic lymphocytic leukemia
compared to ibrutinib and obinutuzumab.
-
Click here for details...
This phase Ib/II clinical trial studies the side effects and best dose of venetoclax and how
well it works when given together with vincristine liposomal in treating patients with T-cell
or B-cell acute lymphoblastic leukemia that has come back or does not respond to treatment.
Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Drugs used in chemotherapy, such as vincristine liposomal, work in different
ways to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving venetoclax together with vincristine
liposomal may work better in treating patients with acute lymphoblastic leukemia.
-
Click here for details...
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or
nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of
minimal residual disease, defined as the levels of a gene product called bcr-abl in the
blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer
cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and
dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic
myeloid leukemia.
-
Click here for details...
This randomized phase II trial studies how well ruxolitinib phosphate and dasatinib or
nilotinib work in treating patients with chronic myeloid leukemia. Ruxolitinib, dasatinib,
and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth.
-
Click here for details...
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute
lymphoblastic leukemia that has come back (relapsed) or does not response to treatment
(refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop
the growth of cancer cells, either by killing the cells, by stopping them from dividing, or
by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
-
Click here for details...
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed
treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic
lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Starting treatment with the
venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes
for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to
starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
|
